 Vincent Chen
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 3 | 2019 | 215 | 1.440 |
Why?
| | Taiwan | 9 | 2021 | 48 | 0.940 |
Why?
| | Global Burden of Disease | 5 | 2024 | 24 | 0.730 |
Why?
| | Antidepressive Agents | 4 | 2021 | 250 | 0.720 |
Why?
| | Liver Neoplasms | 4 | 2024 | 779 | 0.640 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2018 | 372 | 0.630 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 3 | 2021 | 427 | 0.590 |
Why?
| | Psoriasis | 1 | 2019 | 115 | 0.540 |
Why?
| | Taurine | 1 | 2018 | 41 | 0.530 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2018 | 59 | 0.530 |
Why?
| | Brain Mapping | 1 | 2021 | 536 | 0.520 |
Why?
| | Stomach Neoplasms | 1 | 2019 | 130 | 0.520 |
Why?
| | Methylphenidate | 1 | 2017 | 49 | 0.490 |
Why?
| | Accidents, Traffic | 1 | 2017 | 193 | 0.470 |
Why?
| | Enterovirus Infections | 1 | 2018 | 173 | 0.460 |
Why?
| | Suicidal Ideation | 1 | 2021 | 577 | 0.430 |
Why?
| | Dementia | 1 | 2019 | 325 | 0.430 |
Why?
| | Bipolar Disorder | 1 | 2017 | 278 | 0.420 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2018 | 302 | 0.410 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2024 | 98 | 0.390 |
Why?
| | Incidence | 6 | 2024 | 2915 | 0.350 |
Why?
| | Fractures, Bone | 1 | 2017 | 426 | 0.340 |
Why?
| | Infant, Premature | 1 | 2015 | 619 | 0.330 |
Why?
| | Mothers | 1 | 2015 | 767 | 0.290 |
Why?
| | Case-Control Studies | 4 | 2019 | 3619 | 0.270 |
Why?
| | Hospitalization | 1 | 2018 | 2458 | 0.270 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2015 | 891 | 0.250 |
Why?
| | Global Health | 3 | 2024 | 404 | 0.250 |
Why?
| | Databases, Factual | 4 | 2024 | 1500 | 0.240 |
Why?
| | Cohort Studies | 5 | 2021 | 5992 | 0.240 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2030 | 0.230 |
Why?
| | Male | 19 | 2024 | 72817 | 0.220 |
Why?
| | GTP Phosphohydrolases | 1 | 2025 | 93 | 0.210 |
Why?
| | Population Surveillance | 2 | 2019 | 485 | 0.210 |
Why?
| | Proportional Hazards Models | 2 | 2018 | 1332 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 186 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 297 | 0.200 |
Why?
| | Logistic Models | 2 | 2019 | 2130 | 0.200 |
Why?
| | Comorbidity | 2 | 2019 | 1659 | 0.190 |
Why?
| | Female | 19 | 2024 | 78763 | 0.190 |
Why?
| | Humans | 27 | 2025 | 145491 | 0.190 |
Why?
| | Transcription Factors, TFIII | 1 | 2022 | 1 | 0.190 |
Why?
| | Mitochondrial Proteins | 1 | 2025 | 262 | 0.190 |
Why?
| | Thymoma | 1 | 2022 | 37 | 0.180 |
Why?
| | Thymus Neoplasms | 1 | 2022 | 30 | 0.180 |
Why?
| | Transcription Factors, TFII | 1 | 2022 | 44 | 0.180 |
Why?
| | Middle Aged | 11 | 2024 | 36176 | 0.180 |
Why?
| | Cardiovascular Diseases | 3 | 2024 | 2185 | 0.180 |
Why?
| | Glioma | 2 | 2025 | 429 | 0.180 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2022 | 52 | 0.180 |
Why?
| | Developing Countries | 1 | 2024 | 317 | 0.180 |
Why?
| | Socioeconomic Factors | 2 | 2024 | 1327 | 0.170 |
Why?
| | Aged | 7 | 2024 | 26125 | 0.170 |
Why?
| | Drug Therapy | 1 | 2021 | 84 | 0.160 |
Why?
| | Adolescent | 8 | 2024 | 22485 | 0.160 |
Why?
| | Alcoholism | 2 | 2024 | 821 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2023 | 265 | 0.160 |
Why?
| | Young Adult | 7 | 2024 | 14192 | 0.160 |
Why?
| | Thalamus | 1 | 2021 | 127 | 0.150 |
Why?
| | Benzodiazepines | 1 | 2020 | 168 | 0.150 |
Why?
| | Adult | 11 | 2024 | 40707 | 0.150 |
Why?
| | Hyponatremia | 1 | 2019 | 43 | 0.150 |
Why?
| | Odds Ratio | 2 | 2018 | 1082 | 0.140 |
Why?
| | Hep G2 Cells | 1 | 2018 | 75 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2025 | 917 | 0.140 |
Why?
| | Risk Factors | 3 | 2018 | 10874 | 0.140 |
Why?
| | Rats, Inbred SHR | 1 | 2018 | 36 | 0.140 |
Why?
| | Rats, Inbred WKY | 1 | 2018 | 35 | 0.140 |
Why?
| | Sodium | 1 | 2019 | 198 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2020 | 287 | 0.140 |
Why?
| | Neostriatum | 1 | 2018 | 37 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5891 | 0.130 |
Why?
| | Enterovirus | 1 | 2018 | 83 | 0.130 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2018 | 92 | 0.130 |
Why?
| | Lithium | 1 | 2017 | 40 | 0.130 |
Why?
| | Survivors | 1 | 2021 | 521 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1509 | 0.130 |
Why?
| | Brain Neoplasms | 2 | 2025 | 1329 | 0.130 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3537 | 0.130 |
Why?
| | Prevalence | 4 | 2024 | 2855 | 0.130 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2018 | 153 | 0.130 |
Why?
| | Brain | 2 | 2021 | 2944 | 0.130 |
Why?
| | Aorta | 1 | 2020 | 439 | 0.120 |
Why?
| | Aortic Valve | 1 | 2020 | 364 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2021 | 17269 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2017 | 148 | 0.120 |
Why?
| | Risk | 1 | 2019 | 917 | 0.120 |
Why?
| | Hepatitis B, Chronic | 1 | 2016 | 22 | 0.120 |
Why?
| | Corpus Striatum | 1 | 2018 | 179 | 0.120 |
Why?
| | Brief Psychiatric Rating Scale | 1 | 2015 | 7 | 0.120 |
Why?
| | Sex Factors | 2 | 2019 | 2110 | 0.110 |
Why?
| | Dopamine | 1 | 2018 | 295 | 0.110 |
Why?
| | Renal Dialysis | 1 | 2019 | 465 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2024 | 1097 | 0.110 |
Why?
| | Depressive Disorder | 1 | 2018 | 387 | 0.110 |
Why?
| | Anticonvulsants | 1 | 2017 | 246 | 0.110 |
Why?
| | Prefrontal Cortex | 1 | 2018 | 334 | 0.110 |
Why?
| | Child, Preschool | 3 | 2018 | 11837 | 0.100 |
Why?
| | Infant | 2 | 2018 | 10064 | 0.100 |
Why?
| | Cognitive Dysfunction | 1 | 2019 | 470 | 0.100 |
Why?
| | Depression | 2 | 2021 | 1573 | 0.100 |
Why?
| | Connexin 43 | 1 | 2013 | 36 | 0.100 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2013 | 72 | 0.100 |
Why?
| | Dacarbazine | 1 | 2013 | 100 | 0.090 |
Why?
| | Mitochondria | 2 | 2025 | 990 | 0.090 |
Why?
| | Computational Biology | 1 | 2017 | 687 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2950 | 0.090 |
Why?
| | Machine Learning | 1 | 2018 | 590 | 0.090 |
Why?
| | Myocardium | 1 | 2017 | 932 | 0.090 |
Why?
| | Patient Compliance | 1 | 2016 | 587 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3340 | 0.090 |
Why?
| | Child | 4 | 2024 | 22680 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1134 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3897 | 0.080 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 482 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1855 | 0.080 |
Why?
| | Rats | 1 | 2018 | 5581 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2021 | 2373 | 0.070 |
Why?
| | Liver Cirrhosis | 2 | 2023 | 287 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4559 | 0.060 |
Why?
| | Alcohol Drinking | 2 | 2024 | 837 | 0.060 |
Why?
| | Animals | 4 | 2025 | 38141 | 0.060 |
Why?
| | Registries | 1 | 2015 | 2410 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2025 | 46 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2017 | 6437 | 0.050 |
Why?
| | Mitochondrial Dynamics | 1 | 2025 | 40 | 0.050 |
Why?
| | Apoptosis | 1 | 2013 | 2411 | 0.050 |
Why?
| | Phospholipases | 1 | 2023 | 14 | 0.050 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2023 | 25 | 0.050 |
Why?
| | Acyltransferases | 1 | 2023 | 78 | 0.050 |
Why?
| | Metabolic Diseases | 1 | 2024 | 114 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18338 | 0.050 |
Why?
| | Cost of Illness | 1 | 2024 | 324 | 0.040 |
Why?
| | Fatty Liver | 1 | 2024 | 254 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 456 | 0.040 |
Why?
| | Sexism | 1 | 2020 | 69 | 0.040 |
Why?
| | Bias | 1 | 2020 | 198 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5202 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2020 | 420 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2015 | 3917 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3125 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2025 | 2499 | 0.030 |
Why?
| | Mutation | 2 | 2022 | 4093 | 0.030 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 82 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 1378 | 0.030 |
Why?
| | Neuroimaging | 1 | 2018 | 293 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2023 | 2146 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2355 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1895 | 0.030 |
Why?
| | Hemodynamics | 1 | 2020 | 1116 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2021 | 11831 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2025 | 5989 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1156 | 0.020 |
Why?
| | Anxiety | 1 | 2021 | 1127 | 0.020 |
Why?
| | Annexin A5 | 1 | 2013 | 22 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2015 | 243 | 0.020 |
Why?
| | Age of Onset | 1 | 2015 | 554 | 0.020 |
Why?
| | Fluoresceins | 1 | 2013 | 48 | 0.020 |
Why?
| | Cytochromes c | 1 | 2013 | 52 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2017 | 441 | 0.020 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 544 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2019 | 663 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2823 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1369 | 0.020 |
Why?
| | Transfection | 1 | 2013 | 925 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 632 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1304 | 0.020 |
Why?
| | Phosphorylation | 1 | 2013 | 1707 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 6070 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1392 | 0.010 |
Why?
| | Blood Glucose | 1 | 2015 | 2330 | 0.010 |
Why?
| | Insulin | 1 | 2015 | 2506 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8326 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 7171 | 0.010 |
Why?
|
|
Chen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|